Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Premi a la trajectòria investigadora als Hospitals de l'ICS

IP: Rafael Simó Canonge
Collaborators: -
Funding agency: Institut Català de la Salut
Funding: 5000
Reference: ICS/TRAJECTORIA.HOSP/2021/SIMÓ
Duration: 28/06/2021 - 28/06/2021

Beques de Formació de Personal Investigador (FPI) Identificación de los mediadores comunes a la neurodegeneracion inducida por la diabetes en retina y cerebro / Unraveling the common mediators of retinal and brain diabetes-induced neurodegeneration (U

IP: Rafael Simó Canonge
Collaborators: Beques de Formació de Personal Investigador (FPI) Identificación de los mediadores comunes a la neurodegeneracion inducida po, Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 98960
Reference: PRE2020-095747
Duration: 01/09/2021 - 30/08/2025

Ministerio de Ciencia

Estudio de seguridad y eficacia de la sitagliptina en colirio para el tratamiento de los estadios iniciales de retinopatía diabética.

IP: Rafael Simó Canonge
Collaborators: Marc Rivas Agudo, Cristina Hernández Pascual, José García Arumí
Funding agency: Instituto de Salud Carlos III
Funding: 573650
Reference: ICI20/00129
Duration: 01/01/2021 - 31/10/2026

H2O Health Outcomes Observatory

IP: Yolima Cossio Gil
Collaborators: Cristina Hernández Pascual, Natalia Borruel Sainz, Gemma Galán Martinez, Monica Sanchez Bartres, Marta Ferri Peradalta, Rafael Simó Canonge, Joan Carles Peiró Ruiz
Funding agency: The Innovative Medicines Initiative
Funding: 1097257.5
Reference: H2O_IMI2-2020
Duration: 01/10/2020 - 30/09/2025

Related news

The publications update the pharmacological management guideline for obesity and its complications and present the first European comprehensive management guideline for patients with obesity treated with medications.

The study evaluates elecoglipron and shows improvements in glycemic control and body weight compared with placebo.

The study is expected to contribute to the identification of new therapeutic targets and the development of nutritional strategies to improve health.

Related professionals

Maria Arbat i Jubinyà

Maria Arbat i Jubinyà

Predoctoral researcher
Protein kinases in cancer research
Read more
Amina Coucous

Amina Coucous

Research assistant
Infectious Diseases
Read more
Lourdes Emilia Chavarría González

Lourdes Emilia Chavarría González

Research technician
Shock, Organ Dysfunction and Resuscitation
Read more
Aina Alexia Aguayo Holguin

Aina Alexia Aguayo Holguin

Gestió i Administració
Clinical Research Development Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.